Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264238 · ClinicalTrials.gov registry record · Phase 1
Memantine Augmentation in Obsessive-Compulsive Disorder
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00264238: Completed Phase 1 study, sponsored by Stanford University.
NCT00264238 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00264238, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).
Interventions
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00264238
The ClinicalTrials.gov registry entry for NCT00264238 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Memantine is the first listed.
NCT00264238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00264238 about?
NCT00264238 is a clinical study titled "Memantine Augmentation in Obsessive-Compulsive Disorder". The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).
What is the current status of trial NCT00264238?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2006-01. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00264238?
The interventions under investigation include: Memantine (DRUG).
Who is sponsoring clinical trial NCT00264238?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.